泰德医药(3880.HK)公布，中国证监会已受理公司H股全流通计划的申请。根据相关申请文件，该公司已申请将6820.11万股已发行非上市股份转换为H股，有关股份占公司已发行股本总额约48.1%。在取得所有相关批准后及在遵守所有适用法律、法规及规章的前提下，该等非上市股份将转换为H股，且公司将申请批准该等H股在联交所主板上市及买卖。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.